Budget impact analysis of medicines: updated systematic review and implications

被引:31
作者
Faleiros, Daniel Resende [1 ]
Alvares, Juliana [1 ]
Almeida, Alessandra Maciel [1 ]
de Araujo, Vania Eloisa [3 ]
Gurgel Andrade, Eli Iola [2 ]
Godman, Brian B. [4 ,5 ,6 ]
Acurcio, Francisco A. [1 ,2 ]
Guerra Junior, Augusto A. [1 ]
机构
[1] Univ Fed Minas Gerais, Coll Pharm, Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Coll Med, Belo Horizonte, MG, Brazil
[3] Pontificia Univ Catolica Minas Gerais, Coll Dent, Belo Horizonte, MG, Brazil
[4] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland
[5] Karolinska Inst, Div Clin Pharmacol, Stockholm, Sweden
[6] Univ Liverpool, Liverpool Hlth Econ Ctr, Liverpool L69 3BX, Merseyside, England
关键词
systematic review; Budget impact analyses; medicines; drugs; guidelines; RENAL-CELL CARCINOMA; COST-EFFECTIVENESS; ORPHAN DRUGS; ECONOMIC-IMPACT; HEPATITIS-C; RESOURCE IMPLICATIONS; RHEUMATOID-ARTHRITIS; 2ND-LINE TREATMENT; SMOKING-CESSATION; MANAGING ADULTS;
D O I
10.1586/14737167.2016.1159958
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This evaluation determines whether published studies to date meet the key characteristics identified for budget impact analyses (BIA) for medicines, accomplished through a systematic review and assessment against identified key characteristics. Studies from 2001-2015 on 'budget impact analysis' with 'drug' interventions were assessed, selected based on their titles/abstracts and full texts, and their characteristics checked according to key criteria. Out of 1,984 studies, 92 were subsequently identified for review. Of these, 95% were published in Europe and the USA. 2012 saw the largest number of publications (16%) with a decline thereafter. 48% met up to 7 out of the 9 key characteristics. Only 22% stated no conflict of interest. The results indicate low adherence to the key characteristics that should be considered for BIAs and strong conflict of interest. This is an issue since BIAs can be of fundamental importance in managing the entry of new medicines including reimbursement decisions.
引用
收藏
页码:257 / 266
页数:10
相关论文
共 107 条
[1]   THE IMPACT OF TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION ON THE BELGIAN HEALTHCARE SYSTEM: RESULTS FROM A BUDGET IMPACT MODEL [J].
Annemans, L. ;
Eijgelshoven, I ;
Smet, A. ;
Jacobs, A. ;
Bergman, G. .
ACTA CLINICA BELGICA, 2012, 67 (02) :108-119
[2]  
[Anonymous], COST EFF RESOUR ALLO
[3]  
[Anonymous], BR J CARDIOL
[4]  
[Anonymous], BMC INFECT DIS
[5]  
[Anonymous], PHARMACOECONOMICS
[6]  
Araujo DV., 2007, Int J Atheroscler, V2, P189
[7]   Antibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: a Cost and Budget Impact Analysis in Greek Hospitals [J].
Athanasakis K. ;
Petrakis I. ;
Ollandezos M. ;
Tsoulas C. ;
Patel D.A. ;
Karampli E. ;
Kyriopoulos J. .
Infectious Diseases and Therapy, 2014, 3 (2) :257-268
[8]   Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece [J].
Avgerinou, Georgia ;
Bassukas, Ioannis ;
Chaidemenos, Georgios ;
Katsampas, Andreas ;
Kosmadaki, Marita ;
Kousoulakou, Hara ;
Petridis, Athanasios ;
Schenkel, Brad ;
Sotiriadis, Dimitrios ;
Spiliopoulos, Theofanis ;
Stavropoulos, Panagiotis ;
Toumpi, Evgenia ;
Xaplanteris, Loukas .
BMC DERMATOLOGY, 2012, 12
[9]   The cost-effectiveness and budget impact of Vietnam's methadone maintenance treatment programme in HIV prevention and treatment among injection drug users [J].
Bach Xuan Tran ;
Ohinmaa, Arto ;
Anh Thuy Duong ;
Long Thanh Nguyen ;
Phu Xuan Vu ;
Mills, Steve ;
Houston, Stan ;
Jacobs, Philip .
GLOBAL PUBLIC HEALTH, 2012, 7 (10) :1080-1094
[10]   National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom [J].
Bakhai, A ;
Flather, MD ;
Collinson, JR ;
Stevens, W ;
Normand, C ;
Alemao, E ;
Itzler, R ;
Ben-Joseph, R .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2003, 91 (2-3) :163-172